Neurofibromatosis affects roughly 1 in every 2,500 to 3,000 people born worldwide, making it one of the more common genetic disorders of the nervous system. The vast majority of these cases are neurofibromatosis type 1 (NF1). Two rarer forms, NF2-related schwannomatosis and schwannomatosis, are far less frequent but still affect tens of thousands of people globally.
NF1: The Most Common Form
NF1 accounts for the overwhelming majority of neurofibromatosis cases. It occurs in approximately 1 in 2,500 to 3,000 live births, regardless of geographic region. The condition causes benign tumors to grow along nerves throughout the body, often visible as soft bumps under or on the skin. Many people also develop flat, light-brown patches of skin called café-au-lait spots, which are frequently the first sign noticed in infancy or early childhood.
Symptoms are almost always apparent by age 10, and diagnosis typically happens during childhood. About half of all NF1 cases are inherited from a parent who carries the gene mutation. The other half arise from a new, spontaneous mutation, meaning the child is the first person in their family to have the condition. Because NF1 follows an autosomal dominant inheritance pattern, a parent with NF1 has a 50% chance of passing it to each child.
NF2-Related Schwannomatosis: Much Rarer
NF2-related schwannomatosis (formerly called neurofibromatosis type 2) is estimated to occur in about 1 in 25,000 to 33,000 births worldwide. That makes it roughly 10 times less common than NF1. The condition causes tumors to grow on the nerves responsible for hearing and balance, and it can also affect the spinal cord and other nerves.
An important distinction exists between how many people are born with NF2-related schwannomatosis and how many are living with a diagnosis at any given time. Because the condition is often diagnosed late, especially in people without a family history, and because it can reduce lifespan, the number of people carrying a current diagnosis in the general population is lower: closer to 1 in 50,000 to 60,000. Highly specialized medical centers in England that have tracked these patients for decades report diagnostic prevalence around 1 in 50,500, reflecting improved early detection and better survival over time. A 2024 UK-wide assessment found a prevalence of about 1 in 58,000 across England, with slightly higher numbers (1 in 55,000) in regions with the most thorough tracking.
Schwannomatosis Without NF2
The rarest form, schwannomatosis (not related to NF2), causes painful tumors on nerves but does not typically involve the hearing nerves. Reliable prevalence data is limited, but estimates place it at roughly 1 in 40,000 people or fewer. Because it was only recognized as a distinct condition relatively recently, many cases may go undiagnosed or be confused with the other forms.
Does It Affect Some Groups More Than Others?
NF1 occurs at similar rates across all racial and ethnic groups worldwide. The underlying gene mutation appears with equal frequency regardless of ancestry. However, some complications of NF1 do show differences between populations. A large cross-sectional study found that children with NF1 who were of African or Asian ancestry had significantly lower rates of brain tumor diagnoses compared to children of European ancestry. Hispanic versus non-Hispanic ethnicity did not show a meaningful difference in brain tumor frequency. NF1 affects males and females equally, though some specific complications, like brain tumors in childhood, skew slightly more male.
How NF1 Is Detected
NF1 is usually identified through its visible features rather than a blood test. Café-au-lait spots, freckling in the armpits or groin, and small bumps along nerves are characteristic signs that doctors can spot during a physical exam. Clinical criteria alone are enough for diagnosis in most cases.
Genetic testing is available and can identify the responsible mutation in about 88% to 95% of people who meet the clinical criteria for NF1. Testing is most useful when symptoms are ambiguous, when a child is too young to show all the typical features, or when parents want to confirm the diagnosis for family planning purposes. A negative genetic test does not rule out NF1, since a small percentage of mutations fall outside what current testing methods reliably detect.
Putting the Numbers in Perspective
To get a sense of scale, NF1 is roughly as common as cystic fibrosis and considerably more common than conditions like Huntington’s disease or muscular dystrophy. In a country with 4 million births per year, like the United States, approximately 1,300 to 1,600 babies will be born with NF1 annually. NF2-related schwannomatosis adds roughly 100 to 120 more. At any given time, hundreds of thousands of Americans are living with some form of neurofibromatosis, with NF1 making up the vast majority.
Despite these numbers, neurofibromatosis remains underrecognized outside of genetics and neurology clinics. The wide spectrum of severity contributes to this: some people with NF1 have only mild skin findings and live without significant medical complications, while others develop tumors that require ongoing monitoring and treatment throughout their lives. The condition’s variability means that two people with the same gene mutation, even within the same family, can have very different experiences.